BACKGROUND: Cardiac biomarker release signifying @entity296 post-transcatheter aortic valve replacement (TAVR) is common, yet its clinical impact within a large TAVR cohort receiving differing types of valve and procedural approaches is unknown. OBJECTIVES: This study sought to determine the incidence, clinical impact, and factors associated with cardiac biomarker elevation post TAVR. METHODS: This multicenter study included 1,131 consecutive @entity1 undergoing TAVR with balloon-expandable (58%) or self-expandable (42%) valves. Transfemoral and transapical (TA) approaches were selected in 73.1% and 20.3% of @entity1 , respectively. @entity908 kinase-myocardial band (CK-MB) measurements were obtained at baseline and at several time points within the initial 72 h post TAVR. Echocardiography was performed at baseline and at 6- to 12-month follow-up. RESULTS: Overall, 66% of the TAVR population demonstrated some degree of @entity296 as determined by a rise in CK-MB levels (peak value: 1.6-fold [interquartile range (IQR): 0.9 to 2.8-fold]). A TA approach and major procedural complications were independently associated with higher peak of CK-MB levels (p  < 0.01 for all), which translated into impaired systolic left ventricular function at 6 to 12 months post TAVR (p  < 0.01). A greater rise in CK-MB levels independently associated with an increased 30-day, late (median of 21 [IQR: 8 to 36] months) overall and cardiovascular mortality (p  < 0.001 for all). Any increase in CK-MB levels was associated with poorer clinical outcomes, and there was a stepwise rise in late mortality according to the various degrees of CK-MB increase after TAVR (p  < 0.001). CONCLUSIONS: Some degree of @entity296 was detected in two-thirds of @entity1 post TAVR, especially in those undergoing TA-TAVR or presenting with major procedural complications. A greater rise in CK-MB levels associated with  greater acute and late mortality, imparting a negative impact on left ventricular function.

Predictors and Impact of XXXX  After Transcatheter Aortic Valve Replacement: A Multicenter Registry.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity908 :: ('MESH:D003401', 'Chemical') :: ['Creatine'] @entity296 :: ('MESH:D009202', 'Disease') :: ['myocardial injury']
@entity296 :: (MESH:D009202,Disease) :: ['Myocardial Injury']
